Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Recruiting 1Approved for marketing 1

Sponsor Class

OTHER 5INDUSTRY 4NIH 1NETWORK 1

Study Type

Interventional 2Observational 1Expanded_access 1

Sponsor

Cancer Type

Sarcoma 4

Conditions

Sarcoma 316Gastrointestinal Stromal Tumors 108Neoplasms 105Breast Neoplasms 92Melanoma 81Ovarian Neoplasms 79Neoplasm Metastasis 74Carcinoma, Non-Small-Cell Lung 73Colorectal Neoplasms 69Osteosarcoma 61Stomach Neoplasms 59Pancreatic Neoplasms 55Bone Neoplasms 55Prostatic Neoplasms 51Head and Neck Neoplasms 48Glioblastoma 48Sarcoma, Ewing 47Lung Neoplasms 45Esophageal Neoplasms 42Squamous Cell Carcinoma of Head and Neck 41Carcinoma, Renal Cell 40Uterine Cervical Neoplasms 39Sarcoma, Kaposi 38Lymphoma 37Urinary Bladder Neoplasms 36Sarcoma, Synovial 36Recurrence 35Dendritic Cell Sarcoma, Interdigitating 34Lymphoma, Non-Hodgkin 33Endometrial Neoplasms 33

Interventions

olverembatinib 1avapritinib 16-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × GIST × Sarcoma × Clear all
NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting
40 enrolled
Sarcoma

GIST

NCT03862885 2020-07-27

Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

Blueprint Medicines Corporation

Approved for marketing
Sarcoma

GIST

NCT00618319 2015-10-02

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

Biogen

Phase 2 Completed
20 enrolled
Sarcoma

GIST

NCT01459757 2013-06-19

Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib

Pfizer

Completed
322 enrolled
Sarcoma

GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡